In his first press conference upon winning the presidency, on Wednesday, Trump went up to bat against who he deems public enemy #1: …
By Dirk S. Leach Today, long term investors are challenged in navigating the course and lining up that long drive for a investment …
One of the biggest future trends in healthcare is “personalized medicine”. Personalized medicine refers to medical care based around the genetic makeup of …
Currently, the percentage of Americans who go without coverage for their healthcare needs exceeds that of any other advanced economy. As for individuals …
In a report issued today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Ligand Pharmaceutical (LGND) with a $92.00 price target, following LGND’s announcemet that total revenue for 2Q14 …
In a research report issued today, Roth Capital analyst Ed Arce affirmed a Buy rating on AcelRx Pharmaceuticals Inc. (ACRX) with a $22 price target, which represents 121% upside to the current share …
